• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
【24h】

A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.

机译：接受利妥昔单抗（抗CD20）治疗的SLE患者的纵向分析：与B淋巴细胞恢复相关的因素。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Identifying factors associated with B lymphocyte depletion and recovery may aid the development of individualized treatment regimens, optimizing therapy for patients with autoimmune disease. In this study, 12 patients with active SLE were monitored at baseline and monthly following treatment with rituximab. The number and phenotype of peripheral blood B lymphocytes, T lymphocytes and natural killer cells were correlated with the extent and longevity of B lymphocyte depletion. This analysis generated three candidate biomarkers for lymphocyte monitoring in patients with autoimmune disease who are treated with rituximab: circulating transitional B cells, the kappa:lambda ratio and natural killer cells. Further refinement of these potential biomarkers may lead to a better understanding of the role of B cells in disease pathogenesis and a more rational use of B cell depletion therapies.
机译：识别与B淋巴细胞消耗和恢复相关的因素可能有助于个体化治疗方案的发展，从而优化自身免疫性疾病患者的治疗方法。在这项研究中，在接受利妥昔单抗治疗的基线和每月监测12例活动性SLE患者。外周血B淋巴细胞，T淋巴细胞和自然杀伤细胞的数量和表型与B淋巴细胞耗竭的程度和寿命有关。该分析产生了三种自身免疫疾病患者的三种候选生物标志物，用于监测利妥昔单抗：循环性B细胞，κ：λ比和自然杀伤细胞对自身免疫性疾病的淋巴细胞。这些潜在的生物标志物的进一步完善可能导致人们更好地了解B细胞在疾病发病机理中的作用，并更合理地使用B细胞耗竭疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号